$1.23 Billion is the total value of Perceptive Advisors's 196 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
VYGR | Exit | VOYAGER THERAPEUTICS INC | $0 | – | -650 | -100.0% | 0.00% | – |
ZIOP | Exit | ZIOPHARM ONCOLOGY INC | $0 | – | -1,000 | -100.0% | 0.00% | – |
Exit | AVINGER INC | $0 | – | -1,062 | -100.0% | -0.00% | – | |
BTX | Exit | BIOTIME INC | $0 | – | -13,740 | -100.0% | -0.00% | – |
DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -2,499 | -100.0% | -0.00% | – |
MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -1,540 | -100.0% | -0.00% | – |
JUNO | Exit | JUNO THERAPEUTICS INC | $0 | – | -1,113 | -100.0% | -0.00% | – |
CORT | Exit | CORCEPT THERAPEUTICS INC | $0 | – | -11,000 | -100.0% | -0.00% | – |
Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -2,500 | -100.0% | -0.00% | – | |
ABBV | Exit | ABBVIE INC | $0 | – | -1,250 | -100.0% | -0.01% | – |
DPLO | Exit | DIPLOMAT PHARMACY INC | $0 | – | -2,175 | -100.0% | -0.01% | – |
IMGN | Exit | IMMUNOGEN INC | $0 | – | -25,745 | -100.0% | -0.01% | – |
HLF | Exit | HERBALIFE LTD | $0 | – | -1,250 | -100.0% | -0.01% | – |
AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -6,448 | -100.0% | -0.01% | – |
GNCA | Exit | GENOCEA BIOSCIENCES INC | $0 | – | -17,313 | -100.0% | -0.01% | – |
ZLTQ | Exit | ZELTIQ AESTHETICS INC | $0 | – | -2,638 | -100.0% | -0.01% | – |
Exit | ABBOTT LABS | $0 | – | -3,040 | -100.0% | -0.01% | – | |
NVAX | Exit | NOVAVAX INC | $0 | – | -32,000 | -100.0% | -0.02% | – |
CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -71,124 | -100.0% | -0.02% | – |
CNC | Exit | CENTENE CORP DEL | $0 | – | -4,948 | -100.0% | -0.02% | – |
OPHT | Exit | OPHTHOTECH CORP | $0 | – | -8,145 | -100.0% | -0.03% | – |
Exit | ANTHEM INC | $0 | – | -3,400 | -100.0% | -0.03% | – | |
Exit | ALMOST FAMILY INC | $0 | – | -11,942 | -100.0% | -0.04% | – | |
Exit | AMN HEALTHCARE SERVICES INC | $0 | – | -13,445 | -100.0% | -0.04% | – | |
LXRX | Exit | Lexicon Pharmaceuticals Inc | $0 | – | -50,000 | -100.0% | -0.05% | – |
LPCN | Exit | LIPOCINE INCput | $0 | – | -284,400 | -100.0% | -0.06% | – |
LPCN | Exit | LIPOCINE INCcall | $0 | – | -300,000 | -100.0% | -0.06% | – |
BCLI | Exit | BRAINSTROM CELL THERAPEUTICS | $0 | – | -400,000 | -100.0% | -0.07% | – |
Exit | ARNO THERAPEUTIC INC | $0 | – | -3,463,292 | -100.0% | -0.08% | – | |
GMED | Exit | GLOBUS MED INCcl a | $0 | – | -50,000 | -100.0% | -0.08% | – |
Exit | ABIOMED INC | $0 | – | -14,700 | -100.0% | -0.11% | – | |
PETX | Exit | ARATANA THERAPEUTICS INC | $0 | – | -256,500 | -100.0% | -0.11% | – |
RLYP | Exit | RELYPSA INCput | $0 | – | -100,000 | -100.0% | -0.13% | – |
PGNX | Exit | PROGENICS PHARMACEUTICALSput | $0 | – | -500,000 | -100.0% | -0.15% | – |
Exit | ALLIQUA BIOMEDICAL INC | $0 | – | -1,921,951 | -100.0% | -0.15% | – | |
IONS | Exit | Ionis Pharmaceuticals Ord Shsput | $0 | – | -100,000 | -100.0% | -0.16% | – |
Exit | ADMA BIOLOGICS INC | $0 | – | -398,394 | -100.0% | -0.16% | – | |
Exit | ARDELYX INC | $0 | – | -315,955 | -100.0% | -0.19% | – | |
TKAI | Exit | TOKAI PHARMACEUTICALS INC | $0 | – | -661,041 | -100.0% | -0.25% | – |
TSRO | Exit | TESARO INCput | $0 | – | -50,000 | -100.0% | -0.29% | – |
Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -795,000 | -100.0% | -0.31% | – | |
ADHD | Exit | ALCOBRA LTD | $0 | – | -1,028,272 | -100.0% | -0.32% | – |
Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -165,240 | -100.0% | -0.37% | – | |
AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -485,000 | -100.0% | -0.43% | – |
CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -742,021 | -100.0% | -0.52% | – |
TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDadr | $0 | – | -196,000 | -100.0% | -0.68% | – |
Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -400,000 | -100.0% | -0.69% | – | |
HEDJ | Exit | WISDOMTREE EUROPE HEDGED EQUput | $0 | – | -200,000 | -100.0% | -0.70% | – |
VBIV | Exit | VBI VACCINES INC | $0 | – | -3,058,433 | -100.0% | -0.84% | – |
STJ | Exit | ST JUDE MEDICAL | $0 | – | -233,000 | -100.0% | -1.26% | – |
SRPT | Exit | Sarepta Therapeutics Inccall | $0 | – | -979,200 | -100.0% | -1.30% | – |
CPXX | Exit | CELATOR PHARMACEUTICALS INC | $0 | – | -838,400 | -100.0% | -1.75% | – |
XBI | Exit | STREETTRACKS SPDR BIOTEC ETFput | $0 | – | -500,000 | -100.0% | -1.88% | – |
MDVN | Exit | MEDIVATION INC | $0 | – | -760,000 | -100.0% | -3.18% | – |
SRPT | Exit | Sarepta Therapeutics Incput | $0 | – | -7,619,300 | -100.0% | -10.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D | 2024-03-20 |
SC 13G | 2024-03-14 |
SC 13G | 2024-03-11 |
SC 13G/A | 2024-03-06 |
SC 13D/A | 2024-03-01 |
SC 13G | 2024-03-01 |
SC 13D/A | 2024-02-29 |
13F-HR/A | 2024-02-26 |
SC 13G/A | 2024-02-23 |
4 | 2024-02-21 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.